ATE384130T1 - Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe - Google Patents

Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe

Info

Publication number
ATE384130T1
ATE384130T1 AT97936881T AT97936881T ATE384130T1 AT E384130 T1 ATE384130 T1 AT E384130T1 AT 97936881 T AT97936881 T AT 97936881T AT 97936881 T AT97936881 T AT 97936881T AT E384130 T1 ATE384130 T1 AT E384130T1
Authority
AT
Austria
Prior art keywords
meningitidis
lps
bacteria
mutants
deficient
Prior art date
Application number
AT97936881T
Other languages
English (en)
Inventor
Der Ley Peter Van
Liana Steeghs
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Application granted granted Critical
Publication of ATE384130T1 publication Critical patent/ATE384130T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT97936881T 1997-08-21 1997-08-21 Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe ATE384130T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL1997/000474 WO1999010497A1 (en) 1997-08-21 1997-08-21 Novel mutants of gram negative mucosal bacteria and application thereof in vaccines

Publications (1)

Publication Number Publication Date
ATE384130T1 true ATE384130T1 (de) 2008-02-15

Family

ID=19866207

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936881T ATE384130T1 (de) 1997-08-21 1997-08-21 Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe

Country Status (12)

Country Link
US (1) US7011836B1 (de)
EP (1) EP0991761B1 (de)
JP (1) JP2001514001A (de)
AT (1) ATE384130T1 (de)
AU (1) AU755462B2 (de)
CA (1) CA2300854C (de)
DE (1) DE69738472T2 (de)
DK (1) DK0991761T3 (de)
ES (1) ES2301181T3 (de)
NO (1) NO326858B1 (de)
PT (1) PT991761E (de)
WO (1) WO1999010497A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CA2401179A1 (en) * 2000-03-02 2001-09-07 Cp Kelco U.S., Inc. Mutant bacterial strains of the genus sphingomomas deficient in production of polyhydroxybutyrate and process of clarification of sphingans
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP1654364A4 (de) * 2003-08-13 2008-02-13 Novartis Vaccines & Diagnostic Zuführung von immungene codierenden polynukleotiden an inakivierte wirtszellen
EP1706481A2 (de) * 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Impfstoff
WO2006085910A2 (en) * 2004-06-04 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Endotoxin-free moraxella catarrhalis
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101472604B (zh) * 2006-01-19 2013-11-06 研究技术股份有限公司 活的无毒的革兰氏阴性细菌
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
MX340096B (es) 2007-10-19 2016-06-27 Glaxosmithkline Biologicals Sa Formulaciones de vacuna meningococica.
BRPI0907843A2 (pt) 2008-02-21 2015-08-04 Novartis Ag Polipeptídeos de fhbp menigocócicos
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
JP2013503148A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
JP5977678B2 (ja) * 2010-03-12 2016-08-24 リサーチ コーポレーション テクノロジーズ インコーポレイテッド Ｔｌｒ４／ｍｄ−２の外膜アゴニストを欠く生存可能なグラム陰性細菌
MX2012010609A (es) 2010-03-18 2012-10-03 Novartis Ag Vacunas adyuvadas para meningococos serogrupo b.
EP2549990A1 (de) 2010-03-23 2013-01-30 Irm Llc Verbindungen (cysteinbasierte lipopeptide) und zusammensetzungen als tlr2-agonisten zur behandlung von infektionen, entzündungen, atemwegserkrankungen etc.
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
EP2707009A1 (de) 2011-05-12 2014-03-19 Novartis AG Antipyretika zur verbesserung der verträglichkeit von impfstoffen auf vesikelbasis
AU2013214105A1 (en) 2012-02-02 2014-07-24 Novartis Ag Promoters for increased protein expression in meningococcus
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
KR102779223B1 (ko) 2014-02-28 2025-03-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
MX2020008244A (es) 2018-02-06 2020-09-25 Evelo Biosciences Inc Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella.
WO2019169181A1 (en) * 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using lactobacillus salivarius
WO2019169168A1 (en) * 2018-02-28 2019-09-06 Evelo Biosciences, Inc. Compositions and methods for treating cancer using agathobaculum
EP3799884A1 (de) * 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
ATE190502T1 (de) * 1993-05-13 2000-04-15 American Cyanamid Co Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken
US6887483B2 (en) 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria

Also Published As

Publication number Publication date
NO326858B1 (no) 2009-03-02
DK0991761T3 (da) 2008-05-19
NO20000774L (no) 2000-04-14
CA2300854C (en) 2011-04-05
CA2300854A1 (en) 1999-03-04
AU755462B2 (en) 2002-12-12
DE69738472T2 (de) 2009-01-02
JP2001514001A (ja) 2001-09-11
US7011836B1 (en) 2006-03-14
EP0991761A1 (de) 2000-04-12
AU3954097A (en) 1999-03-16
DE69738472D1 (de) 2008-03-06
ES2301181T3 (es) 2008-06-16
NO20000774D0 (no) 2000-02-17
PT991761E (pt) 2008-04-28
EP0991761B1 (de) 2008-01-16
WO1999010497A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
ATE384130T1 (de) Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe
Ames et al. Protein composition of the outer membrane of Salmonella typhimurium: effect of lipopolysaccharide mutations
Skurnik Expression of antigens encoded by the virulence plasmid of Yersinia enterocolitica under different growth conditions
ATE319476T1 (de) Neuartige nicht pyrogene bakterienstämme und ihre verwendung
Kelley et al. Identification and preliminary characterization of Vibrio cholerae outer membrane proteins
Swanson Studies on gonococcus infection. XVIII. 125I-labeled peptide mapping of the major protein of the gonococcal cell wall outer membrane
DE69423383D1 (de) Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
HUP9900768A2 (hu) Photorhabdusból származó inszekticid protein toxinok
Chen et al. Extracellular proteins of Cryptococcus neoformans and host antibody response
Amano et al. Biochemical and immunological comparison of lipopolysaccharides from Bordetella species
Poolman et al. Outer membrane protein serosubtyping of Neisseria meningitidis
Agabian et al. Caulobacter crescentus cell envelope: effect of growth conditions on murein and outer membrane protein composition
Heckels The surface properties of Neisseria gonorrhoeae: topographical distribution of the outer membrane protein antigens
Patel et al. Red blood cells, a source of factors which induce Neisseria gonorrhoeae to resistance to complement-mediated killing by human serum
Zanders et al. Separation and characterization of a protein antigen from cells of Streptococcus mutans
Pugsley et al. Comparison of colicins B-K260 and D-CA23: purification and characterization of the colicins and examination of colicin immunity in the producing strains
DK0563256T3 (da) Anvendelse af værtscelle-phospholipider til inhibering af bakteriekolonisering
Godchaux 3rd et al. Outer membrane polysaccharide deficiency in two nongliding mutants of Cytophaga johnsonae
Blaser et al. Humoral immune response to lipopolysaccharide antigens of Campylobacter jejuni
Zahorchak et al. Transmembrane electrical potential in Rickettsia prowazekii and its relationship to lysine transport
Shannon et al. Lack of dendritic cell maturation following infection by Coxiella burnetii synthesizing different lipopolysaccharide chemotypes
Gorchein The relation between the pigment content of isolated chromatophores and that of the whole cell in Rhodopseudomonas spheroides
FR2517967B1 (de)
Hozbor et al. Use of cyclodextrin as an agent to induce excretion of Bordetella pertussis antigens
Arcidiacono et al. A rapid selective extraction procedure for the outer membrane protein (OmpF) from Escherichia coli

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0991761

Country of ref document: EP